PubMed · 1999 · 134 citations · 17 references
MedicineImmunologyOncologyCancer ImmunologyTumor ImmunologyVaccinologyAntitumor T Cell ResponsesCancer ImmunotherapyCancer VaccinesCytotoxic T Lymphocyte ResponsesTherapeutic VaccinationTumor-associated AntigensAntigen Presenting CellsImmunogenicity Of Tumor AntigensPhagocytic ActivityProcessing Of Tumor AntigensProfessional Antigen-presenting CellsTherapeutic Cancer ImmunizationTumor Antigen-specific Cytotoxic T Lymphocyte ResponsesTumor Immunogenicity
We have reported recently that treatments combining injections of apoptotic bodies from tumor cells and interleukin 2 led to tumor regression and induced specific protection. In the present study, we show that tumor-bearing rats were cured with an 80% success rate by injection of antigen-presenting cells (APCs) that had phagocytosed apoptotic bodies derived from poorly immunogenic tumor cells, whereas phagocytic cells exposed to nonapoptotic tumor cell extracts were essentially without effect. In addition, curative vaccination using APCs that had phagocytosed apoptotic bodies generated a tumor-specific cytotoxic T-cell response and long-term protection from parental tumor challenge. Thus, systems using the processing and presentation of antigenic molecules by professional APCs after phagocytosis of apoptotic bodies appear to offer new possibilities for anticancer treatment.
17
Vaccination of melanoma patients with peptide- or tumorlysate-pulsed dendritic cells
Frank O. Nestlé, Selma Alijagic, Michel Gilliet et al. · Nature Medicine · 1998 · 2.9K citations
Medicine, Immunology, Oncology +14
Kayo Inaba, Shannon J. Turley, Fumiya Yamaide et al. · The Journal of Experimental Medicine · 1998 · 624 citations · Full text
David M. Ashley, Brenda Faiola, Smita K. Nair et al. · The Journal of Experimental Medicine · 1997 · 448 citations · Full text
Medicine, Immunology, Oncology +17